ARTA
ARRY

A.R.T. Advisors’s Array Biopharma Inc ARRY Stock Holding History

A.R.T. Advisors’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-23,986
Closed -$585K – 1798
2019
Q1 		$585K Buy
+23,986
New +$499K 0.04% 693
2018
Q3 		– Sell
-98,086
Closed -$1.65M – 1875
2018
Q2 		$1.65M Sell
98,086
-188,231
-66% -$2.99M 0.07% 432
2018
Q1 		$4.67M Buy
+286,317
New +$4.59M 0.19% 118
2017
Q3 		– Sell
-235,352
Closed -$1.97M – 1852
2017
Q2 		$1.97M Sell
235,352
-77,500
-25% -$634K 0.1% 283
2017
Q1 		$2.8M Buy
312,852
+262,852
+526% +$2.8M 0.13% 215
2016
Q4 		$439K Buy
50,000
+20,900
+72% +$154K 0.03% 810
2016
Q3 		$196K Sell
29,100
-237,888
-89% -$920K 0.06% 498
2016
Q2 		$950K Sell
266,988
-14,680
-5% -$47.8K 0.05% 567
2016
Q1 		$830K Sell
281,668
-262,700
-48% -$787K 0.04% 663
2015
Q4 		$2.3M Buy
544,368
+373,110
+218% +$1.7M 0.11% 249
2015
Q3 		$780K Buy
171,258
+113,900
+199% +$675K 0.03% 716
2015
Q2 		$413K Buy
+57,358
New +$423K 0.01% 1062
2014
Q3 		– Sell
-72,683
Closed -$331K – 1641
2014
Q2 		$331K Sell
72,683
-78,040
-52% -$323K 0.02% 951
2014
Q1 		$708K Sell
150,723
-102,676
-41% -$516K 0.04% 625
2013
Q4 		$1.27M Buy
253,399
+2,134
+0.8% +$11.6K 0.07% 396
2013
Q3 		$1.56M Buy
251,265
+168,191
+202% +$999K 0.09% 346
2013
Q2 		$377K Buy
+83,074
New +$447K 0.01% 976

Other funds holding ARRY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

A.R.T. Advisors's ARRY Position: Q2 2019 in Review

A.R.T. Advisors sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 23,986 shares — an estimated $585K sold.

A.R.T. Advisors first reported a position in ARRY in Q2 2013 and held it in 17 quarters. The position peaked at $4.67M in Q1 2018. 319 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

  • A.R.T. Advisors reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 23,986 Array Biopharma Inc shares in Q2 2019, an estimated $585K.
  • A.R.T. Advisors first reported a position in Array Biopharma Inc in Q2 2013 and held it in 17 quarters.
  • A.R.T. Advisors's Array Biopharma Inc position peaked at $4.67M in Q1 2018.
  • 319 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on A.R.T. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.